GSK (GSK)

Sector:

Pharma and Biotech

Index:

FTSE 100

1,507.00p
   
  • Change Today:
      51.00p
  • 52 Week High: 1,766.50
  • 52 Week Low: 1,264.00
  • Currency: UK Pounds
  • Shares Issued: 4,098.64m
  • Volume: 23,131,734
  • Market Cap: £61,766m
  • RiskGrade: 129

News Wires

FDA Approves Promacta(R) (Eltrombopag), the Firs... 20-Nov-2008 PR Newswire
Study Found That Long Term Use of Advair Diskus(... 29-Oct-2008 PR Newswire
GlaxoSmithKline to Acquire Genelabs Technologies... 29-Oct-2008 PR Newswire
New Research Shows Many Patients with Persistent... 28-Oct-2008 PR Newswire
GlaxoSmithKline to Acquire the Leading Dry Mouth... 21-Oct-2008 PR Newswire
GSK Notice of Third Quarter 2008 Results Announc... 20-Oct-2008 PR Newswire
LF Elimination Program Treats Over Half Billion ... 07-Oct-2008 PR Newswire
alli(TM) Partners with Breast Cancer Network of ... 22-Sep-2008 PR Newswire
MultiVu Video Feed: NEW BRAIN IMAGING SHOWS THE ... 18-Sep-2008 PR Newswire
GSK and XenoPort Announce Submission of New Drug... 16-Sep-2008 PR Newswire
A New Interactive Consumer Experience Highlighti... 28-Sep-2007 PR Newswire
AUDIO from Medialink and GlaxoSmithKline: A New ... 28-Sep-2007 PR Newswire
GSK Receives Decision From FDA on Advair(R) 500/... 08-Aug-2007 PR Newswire
GlaxoSmithKline Receives New HHS Order for H5N1 ... 03-Aug-2007 PR Newswire
FDA Issues Second Approvable Letter for Trexima(... 02-Aug-2007 PR Newswire
GlaxoSmithKline Presents Avandia Data To FDA 30-Jul-2007 PR Newswire
FDA Advisory Panel Votes 22 to 1 for Avandia(R) ... 30-Jul-2007 PR Newswire
ChemoCentryx Achieves $5 Million Milestone from ... 24-Jul-2007 PR Newswire
GSK's Cervical Cancer Candidate Vaccine Cervarix... 18-Jul-2007 PR Newswire
Pharmacopeia Advances First Therapeutic Program ... 17-Jul-2007 PR Newswire

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

GSK Market Data

Currency UK Pounds
Share Price 1,507.00p
Change Today 51.00p
% Change 3.50 %
52 Week High 1,766.50
52 Week Low 1,264.00
Volume 23,131,734
Shares Issued 4,098.64m
Market Cap £61,766m
RiskGrade 129

GSK Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
52.41% below the market average52.41% below the market average52.41% below the market average52.41% below the market average52.41% below the market average
26.09% above the sector average26.09% above the sector average26.09% above the sector average26.09% above the sector average26.09% above the sector average
Price Trend
31.87% above the market average31.87% above the market average31.87% above the market average31.87% above the market average31.87% above the market average
56.52% above the sector average56.52% above the sector average56.52% above the sector average56.52% above the sector average56.52% above the sector average
Income
68.22% above the market average68.22% above the market average68.22% above the market average68.22% above the market average68.22% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average
Growth
36.94% below the market average36.94% below the market average36.94% below the market average36.94% below the market average36.94% below the market average
46.67% below the sector average46.67% below the sector average46.67% below the sector average46.67% below the sector average46.67% below the sector average

What The Brokers Say

Strong Buy 4
Buy 2
Neutral 14
Sell 3
Strong Sell 1
Total 24
neutral
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

GSK Dividends

  Latest Previous
  Q1 Q4
Ex-Div 15-May-25 20-Feb-25
Paid 10-Jul-25 10-Apr-25
Amount 16.00p 16.00p

Trades for 30-May-2025

Time Volume / Share Price
16:48 42 @ 1,507.00p
16:47 12,890 @ 1,496.62p
16:25 0 @ 1,514.00p
16:24 0 @ 1,513.00p
16:23 2 @ 1,513.00p

GSK Key Personnel

CEO Emma Walmsley

Top of Page